Heavy falls in AstraZeneca saw London’s FTSE 100 underperform European peers, while investors continue to weigh up developments in the Middle East.The FTSE 100 closed down 16.59 points, 0.2%, at 10,472.45. The FTSE 250 ended up 222.92 points, 1.0%, at 23,240.56, while the AIM All-Share rose 4.18 points, 0.6%, to 762.25.Pharmaceutical firm AstraZeneca sank 6.2% as it said Wainua, a cardiovascular drug that it is developing in partnership with Ionis Pharmaceuticals, did not meet its primary endpoint in a phase three trial.AstraZeneca said Wainua, whose generic name is eplontersen, was being tested in patients with transthyretin-mediated amyloid cardiomyopathy. The drug did not meet its primary efficacy endpoint in terms of mortality or cardiovascular clinical events up to 140 weeks, compared